
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Pharmaceutical science & technology news.
over 23 years ago
BIO Updateover 23 years ago
Designing Transfer Carts for Class 100 Conditionsover 23 years ago
An Update on Osmotic Drug Deliveryover 23 years ago
New FDA Initiatives Aim to Spur Innovationover 23 years ago
Interphex Serves as a Showcase for New Materials and Machinesover 23 years ago
In the Spotlight August 2003





